Allient (ALNT) Competitors $39.35 -0.15 (-0.38%) As of 11:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALNT vs. TXG, TRNS, EYPT, LAB, CTKB, AEHR, QSI, QTRX, SENS, and MASSShould you be buying Allient stock or one of its competitors? The main competitors of Allient include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Standard BioTools (LAB), Cytek Biosciences (CTKB), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), Senseonics (SENS), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Allient vs. Its Competitors 10x Genomics Transcat Eyepoint Pharmaceuticals Standard BioTools Cytek Biosciences Aehr Test Systems Quantum-Si Quanterix Senseonics 908 Devices 10x Genomics (NASDAQ:TXG) and Allient (NASDAQ:ALNT) are both small-cap measuring and control equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability. Which has higher valuation and earnings, TXG or ALNT? Allient has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.48-$182.63M-$1.30-9.46Allient$529.97M1.26$13.17M$0.5966.69 Do institutionals and insiders have more ownership in TXG or ALNT? 84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 61.6% of Allient shares are held by institutional investors. 9.4% of 10x Genomics shares are held by company insiders. Comparatively, 15.6% of Allient shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is TXG or ALNT more profitable? Allient has a net margin of 1.90% compared to 10x Genomics' net margin of -25.14%. Allient's return on equity of 8.45% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-25.14% -23.22% -18.02% Allient 1.90%8.45%3.86% Do analysts prefer TXG or ALNT? 10x Genomics presently has a consensus target price of $14.13, suggesting a potential upside of 14.86%. Allient has a consensus target price of $31.00, suggesting a potential downside of 21.22%. Given 10x Genomics' higher possible upside, equities analysts clearly believe 10x Genomics is more favorable than Allient.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 5 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.46Allient 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more risk & volatility, TXG or ALNT? 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Allient has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Does the media prefer TXG or ALNT? In the previous week, Allient had 1 more articles in the media than 10x Genomics. MarketBeat recorded 5 mentions for Allient and 4 mentions for 10x Genomics. Allient's average media sentiment score of 0.73 beat 10x Genomics' score of 0.50 indicating that Allient is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allient 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAllient beats 10x Genomics on 10 of the 16 factors compared between the two stocks. Get Allient News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNT vs. The Competition Export to ExcelMetricAllientELEC IndustryComputer SectorNASDAQ ExchangeMarket Cap$666.20M$5.01B$28.50B$9.41BDividend Yield0.30%2.97%3.10%4.06%P/E Ratio66.7031.8033.6319.89Price / Sales1.262.251,749.91101.69Price / Cash13.0122.7037.8657.94Price / Book2.502.267.605.67Net Income$13.17M$171.53M$779.03M$257.97M7 Day Performance1.97%1.33%2.21%2.41%1 Month Performance14.52%4.02%7.34%11.57%1 Year Performance42.11%-3.26%52,800.69%18.70% Allient Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNTAllient2.2694 of 5 stars$39.35-0.4%$31.00-21.2%+39.3%$666.20M$529.97M66.702,525TXG10x Genomics4.4659 of 5 stars$11.92-8.4%$14.96+25.5%-37.2%$1.60B$610.78M-9.171,240TRNSTranscat2.817 of 5 stars$86.35-3.9%$114.00+32.0%-40.1%$837.47M$278.42M55.351,245EYPTEyepoint Pharmaceuticals1.5046 of 5 stars$9.49-2.4%$25.67+170.5%+6.5%$668.85M$43.27M-3.94120LABStandard BioTools3.8429 of 5 stars$1.28-5.2%$2.50+95.3%-46.1%$512.76M$174.43M-3.66620Positive NewsCTKBCytek Biosciences3.0904 of 5 stars$3.40-9.6%$5.60+64.7%-50.7%$476.24M$200.45M-37.77500AEHRAehr Test Systems1.6272 of 5 stars$14.82-5.0%$25.00+68.7%-24.9%$464.43M$66.22M19.0090QSIQuantum-Si2.0655 of 5 stars$1.83-14.5%$3.48+89.9%+56.9%$392.69M$3.06M-2.69150QTRXQuanterix2.8231 of 5 stars$6.30-9.7%$15.60+147.6%-65.0%$348.68M$137.42M-4.85460News CoveragePositive NewsAnalyst RevisionSENSSenseonics2.0126 of 5 stars$0.49-2.6%$1.55+216.8%+19.8%$320.11M$23.68M-3.7690Analyst ForecastAnalyst RevisionGap UpMASS908 Devices1.1343 of 5 stars$6.41-3.6%$5.33-16.8%+11.5%$238.48M$59.63M-11.8760Analyst Revision Related Companies and Tools Related Companies 10x Genomics Alternatives Transcat Alternatives Eyepoint Pharmaceuticals Alternatives Standard BioTools Alternatives Cytek Biosciences Alternatives Aehr Test Systems Alternatives Quantum-Si Alternatives Quanterix Alternatives Senseonics Alternatives 908 Devices Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNT) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredNew crypto laws coming. Will you win or lose?Washington’s first-ever “Crypto Week” could trigger a major Bitcoin surge — but one trader says don’t just buy...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allient Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allient With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
